PMID- 37701387
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230915
IS  - 2532-8689 (Electronic)
IS  - 1124-9390 (Print)
IS  - 1124-9390 (Linking)
VI  - 31
IP  - 3
DP  - 2023
TI  - Therapy initiation and rapid start with Bictegravir/Emtricitabine/Tenofovir 
      Alafenamide in PLWH.
PG  - 277-282
LID - 10.53854/liim-3103-2 [doi]
AB  - Advanced HIV naive represents an unfavorable prognostic condition due to a 
      persistent high risk of death, increased probability of virological failure, 
      immunologic impairment, clinical progression, and immune reconstitution 
      inflammatory syndrome (IRIS), cumulative adverse drug events, drug-drug 
      interactions and increased healthcare costs. Currently, all international 
      guidelines recommend the rapid initiation of ART, especially in late-stage naive 
      patients. Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF), due to its 
      efficacy high genetic barrier, good safety profile, and low DDI potential, is one 
      of the regimens recommended for overall rapid initiation by international 
      guidelines. B/F/TAF has been tested in observational or uncontrolled pilot 
      studies (OPERA, RAINBOW), while a large randomized controlled trial is currently 
      ongoing (LAPTOP). In conclusion, B/F/TAF is an ideal combination for the 
      initiation of antiretroviral therapy, particularly in the HIV late presenter or 
      advanced HIV disease patient, even in the context of rapid start or same-day 
      treatment regimens, where the initiation of treatment usually occurs in the 
      absence of information on viral load, CD4 count, biochemical profile and HIV 
      transmitted resistance.
FAU - Antinori, Andrea
AU  - Antinori A
AD  - Clinical Department of Infectious Diseases, National Institute for Infectious 
      Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230901
PL  - Italy
TA  - Infez Med
JT  - Le infezioni in medicina
JID - 9613961
PMC - PMC10495053
OTO - NOTNLM
OT  - Bictegravir
OT  - Emtricitabile
OT  - PLWH
OT  - Tenofovir
COIS- Conflict of interest None to declare.
EDAT- 2023/09/13 06:42
MHDA- 2023/09/13 06:43
PMCR- 2023/09/01
CRDT- 2023/09/13 04:04
PHST- 2023/06/25 00:00 [received]
PHST- 2023/07/31 00:00 [accepted]
PHST- 2023/09/13 06:43 [medline]
PHST- 2023/09/13 06:42 [pubmed]
PHST- 2023/09/13 04:04 [entrez]
PHST- 2023/09/01 00:00 [pmc-release]
AID - 1124-9390_31_3_2023_277-282 [pii]
AID - 10.53854/liim-3103-2 [doi]
PST - epublish
SO  - Infez Med. 2023 Sep 1;31(3):277-282. doi: 10.53854/liim-3103-2. eCollection 2023.